| Alzheimer’s disease is a chronic neurodegenerative disease mainly sufferedby the elder. With the acceleration of the aging process of the world’spopulation, Alzheimer’s disease has already become a grave threat to oldpersons’ health life.Analysising the clinical pathological symptoms and features molecularbiology of Alzheimer’s disease, AD is closely connected with diabetes. A lot ofreports show that GLP-1R has played an important role in both two diseases.GLP-1R agonists could improve and relieve the symptoms of the two diseases.In this paper, GLP-1R agonist Ex-4(Ex-4) which was used in treatment of TypeII diabetes was chose to treat APP/PS1mice with two doses (25nmol/kg and0.36nmol/kg) of Ex-4and PLGA-Ex-4release microspheres.The changes of AD rats’ behavior were evaluated through the Morris watermaze test. The results showed that the level of cognitive and memory functionof AD mice groups was significantly improved after the treatment of high dosesof Ex-4and PLGA-Ex-4release microsphere, but the improvement of thelow-dose group was not obvious.By pathology examination, we found that high dose of Ex-4had a goodprotective effect for hippocampal pyramidal cells, and it could inhibit or reduceAβ deposition and the amount of soluble Aβ1-40and Aβ1-42in the brain.However, the effects of PLGA-Ex-4microspheres and low-dose Ex-4wereweak relatively.By testing the influence of Ex-4on the number of GLP-1R in brains of ADmice, the results showed that Ex-4could regulate up the expression ofGLP-1R in the brain and the upregulation of PLGA-Ex-4microspheres wasmost significant.In summary, this study shows a certain therapeutic effect of Ex-4forAlzheimer’s mice, which consistent with other papers. With further study of its therapeutic mechanism, mode of administrations and dosage forms, Ex-4isexpected to become a new drug for clinical treatment of Alzheimer’s disease. |
PDF Full Text Request